Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1996, for OrthoLogic Corp. (Note: The request metadata lists "Capstone Holding Corp.", but the filing text explicitly identifies the registrant as OrthoLogic Corp.). The company is a Delaware corporation focused on the development and sale of orthopedic products, specifically the OrthoLogic 1000 system. As of April 30, 1996, there were 9,853,900 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Net Sales | $6,759,732 | $2,517,083 |
| Gross Margin | $5,637,453 (83.4%) | $1,956,779 (77.7%) |
| Operating Income | $661,694 | ($1,002,301) |
| Net Income | $934,627 | ($935,814) |
| Diluted EPS | $0.09 | ($0.13) |
| Cash and Equivalents | $5,112,403 | $4,303,605 |
| Short-term Investments | $11,209,665 | $0 |
| Total Current Assets | $28,446,392 | $N/A |
| Working Capital | $24,837,034 | $N/A |
| Debt Outstanding | $0 | $0 |
Liquidity: The company held $16.3 million in cash, cash equivalents, and short-term investments as of March 31, 1996. It maintains a $2 million revolving line of credit with no amounts outstanding.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 169% year-over-year, driven primarily by higher sales volumes of the OrthoLogic 1000 product.
- Profitability Turnaround: The company shifted from a net loss of $935,814 in Q1 1995 to a net income of $934,627 in Q1 1996.
- Margin Expansion: Gross margin percentage improved from 78% to 83% due to better absorption of fixed manufacturing costs and a favorable product mix shift.
- Expense Management: While Selling, General, and Administrative (SG&A) expenses rose 89% due to sales-related costs (commissions, royalties), Research and Development (R&D) expenses decreased 11% due to lower patient enrollment in a clinical trial.
- Cash Flow: Net cash used in operating activities was $1.96 million, primarily due to a $2.8 million increase in accounts receivable and inventory buildup. Investing activities consumed $2.24 million, largely for the purchase of short-term investments.
Outlook, Risks, and Unusual Items
- Subsequent Event (Capital Raise): On April 30, 1996, the company completed a public offering of 2,530,000 shares at $31 per share, generating gross proceeds of $78.4 million and net proceeds of approximately $73.5 million.
- Liquidity Outlook: Management anticipates that the proceeds from the secondary offering, combined with product sales and existing cash balances, will be sufficient to meet capital requirements for the foreseeable future.
- Risks: The filing notes that there can be no assurance that additional financing will not be required in the future or that such capital will be available on favorable terms.
- Tax Position: The company has a deferred tax asset of $7.5 million related to Net Operating Loss (NOL) carryforwards, which is fully offset by a valuation allowance. An estimated alternative minimum tax of $15,000 was recognized for the quarter.
- Corporate Actions: Shareholders voted to increase authorized common stock from 15 million to 40 million shares and ratified Deloitte & Touche LLP as independent auditors.
Investor Verification Checklist
- Verify the impact of the $73.5 million net proceeds from the April 30, 1996 stock offering on the balance sheet in the subsequent filing.
- Monitor the collection of the $9.3 million accounts receivable balance, which increased significantly during the quarter.
- Confirm the completion status of the clinical trial mentioned in the R&D expense reduction.
- Review the utilization of the $2 million line of credit and compliance with financial covenants (minimum net worth, quarterly net loss limits).
- Assess the sustainability of the 83% gross margin as production volumes fluctuate.